Loading
Pharmaceutical
9 min read
Areas of Expertise :
Securities, Economics, Economic Damages, Forensic Accounting, Pharmaceutical
Published Date:
Last Modified Date:
Jurisdiction:
Federal. Second Circuit
In In re Teva Securities Litigation (No. 3:17-cv-00558 (SRU), D. Conn.), investors brought a consolidated set of federal securities actions against Teva Pharmaceutical Industries Ltd., related entities, and certain current and former executives, alleging that misstatements and omissions misrepresented the reasons for Teva’s financial results in the generic-drug business. The claims centered on disclosures and related theories asserting that Teva’s results were supported by artificial inflation of prices for certain generic drugs, including allegations framed as collusive price increases, and that the market was misled about the sources and sustainability of those results. The asserted causes of action proceeded under the Securities Exchange Act of 1934 and, for certain offerings, the Securities Act of 1933. On March 9, 2021, the court granted the motion for class certification, appointed Ontario Teachers’ Pension Plan Board and Anchorage Police & Fire Retirement System as Class Representatives, appointed Bleichmar Fonti & Auld LLP as Class Counsel, and denied the motion seeking to exclude the plaintiffs’ market-efficiency expert under Daubert.
The certified class covered purchasers or acquirers in domestic transactions of Teva American Depositary Shares, Teva 7.00% mandatory convertible preferred shares, and specified Teva Finance U.S.-dollar-denominated senior notes during the period from February 6, 2014 through May 10, 2019, inclusive, with additional definitions tied to certain offerings and a Teva employee stock plan. The proposed resolution was presented through a long-form settlement notice describing a $420,000,000 cash settlement fund in exchange for releases, subject to court approval and the notice process. For context grounded in the case record, the litigation’s economics reflects the court’s Rule 23 findings on market efficiency, price impact, and whether a classwide damages methodology could measure alleged losses tied to claimed artificial inflation and later corrective disclosures.
The record reflects that Teva became involved in private securities litigation beginning in or around November 2016, when investors first filed actions alleging misleading statements about the company’s financial condition. These early cases later became part of a broader set of related investor claims that developed over time. The alleged harm theory centered on investor losses following market reactions to information tied to generic-drug pricing and competition, placing healthcare industry economics at the center of the dispute.
The first-filed lawsuit was transferred from the Central District of California to the U.S. District Court for the District of Connecticut in April 2017. After transfer, the matter proceeded under the procedural framework governing federal securities class actions, including lead-plaintiff and lead-counsel appointment processes. The allegations continued to focus on Teva’s investor-facing disclosures regarding performance in the generic-drug market.
In July 2017, the court appointed Ontario Teachers’ Pension Plan Board as lead plaintiff and approved Bleichmar Fonti & Auld LLP as lead counsel. That appointment established the leadership structure for pursuing the claims on behalf of the proposed class. The litigation continued to develop around whether statements and omissions concerning generic-drug pricing strategy and competitive conditions were materially misleading to investors.
On September 25, 2019, the court granted in part and denied in substantial part the defendants’ motion to dismiss the Second Amended Consolidated Class Action Complaint. This ruling allowed significant portions of the case to proceed beyond the pleadings stage while narrowing the claims that remained in dispute. The surviving issues continued to address whether the market was misled about the drivers of Teva’s financial results in a pricing-pressured healthcare drug environment.
By early 2020, the Teva securities actions were proceeding under consolidated case management in the District of Connecticut. The court entered a consolidation order dated March 10, 2020, aligning overlapping actions under a unified structure and coordinated case-management approach. This procedural step set the stage for class proceedings where marketwide proof and common evidence became central.
On June 19, 2020, the class representatives filed a motion for class certification. The record reflects extensive briefing and expert discovery, including the exchange of expert reports and multiple expert depositions, as the parties litigated classwide proof issues. The certification record included plaintiffs’ market-efficiency analysis offered by Dr. Tabak, along with defense expert reports from Dr. Mukesh Bajaj and Dr. John McConnell challenging the reliability and interpretation of that analysis. Defendants also relied on an expert report from Christopher M. James addressing Teva’s disclosures, publicly available and commercial drug-pricing data, analyst coverage, and issues related to isolating damages across multiple liability theories, all presented for Rule 23 purposes.
On March 9, 2021, the court granted the motion for class certification and appointed Ontario Teachers’ Pension Plan Board and Anchorage Police & Fire Retirement System as class representatives, with Bleichmar Fonti & Auld LLP as class counsel. In the same decision set, the court denied a Daubert motion directed at Dr. Tabak’s market-efficiency analysis, while also evaluating and rejecting defense critiques offered by Dr. Mukesh Bajaj and Dr. John McConnell, as well as damages-related arguments supported by Christopher M. James. The court concluded that the plaintiffs satisfied Rule 23 requirements based on common evidence, expressly noting that these expert disputes were resolved solely for class-certification purposes and did not constitute findings on liability or ultimate merits.
Settlement materials describe a stipulation dated January 18, 2022 setting out a proposed resolution of the litigation. The proposal contemplated a $420,000,000 cash settlement fund, subject to court approval and a formal notice process for class members. The settlement presentation framed investor losses as tied to market pricing responses to information concerning competition and pricing dynamics in the generic-drug segment.
The long-form settlement notice set May 2, 2022 as the deadline for class members to submit written requests for exclusion. The notice also described deadlines for objections and for filing notices of intention to appear. These procedural steps reflect standard resolution mechanics in securities class actions focused on market impact and investor-loss calculations.
The long-form notice scheduled a settlement hearing for June 2, 2022, at which the court considered whether to approve the proposed settlement. Case summaries and settlement materials describe the court granting final approval of the $420 million settlement on the hearing date. The approved settlement resolved claims tied to purchases or acquisitions of specified Teva securities during defined periods, with eligibility and allocation governed by the settlement terms.
Court:
United States District Court for the District of Connecticut
Case Name:
In re Teva Securities Litigation
Securities Class Action
Securities Fraud
Securities Litigation
Financial Analysis
Economic Analysis
Institutional investor
Investment Fraud
Pharmacoeconomics
In In re Teva Securities Litigation (No. 3:17-cv-00558 (SRU), D. Conn.), investors brought a consolidated set of federal securities actions against Teva Pharmaceutical Industries Ltd., related entities, and certain current and former executives, alleging that misstatements and omissions misrepresented the reasons for Teva’s financial results in the generic-drug business. The claims centered on disclosures and related theories asserting that Teva’s results were supported by artificial inflation of prices for certain generic drugs, including allegations framed as collusive price increases, and that the market was misled about the sources and sustainability of those results. The asserted causes of action proceeded under the Securities Exchange Act of 1934 and, for certain offerings, the Securities Act of 1933. On March 9, 2021, the court granted the motion for class certification, appointed Ontario Teachers’ Pension Plan Board and Anchorage Police & Fire Retirement System as Class Representatives, appointed Bleichmar Fonti & Auld LLP as Class Counsel, and denied the motion seeking to exclude the plaintiffs’ market-efficiency expert under Daubert.
The certified class covered purchasers or acquirers in domestic transactions of Teva American Depositary Shares, Teva 7.00% mandatory convertible preferred shares, and specified Teva Finance U.S.-dollar-denominated senior notes during the period from February 6, 2014 through May 10, 2019, inclusive, with additional definitions tied to certain offerings and a Teva employee stock plan. The proposed resolution was presented through a long-form settlement notice describing a $420,000,000 cash settlement fund in exchange for releases, subject to court approval and the notice process. For context grounded in the case record, the litigation’s economics reflects the court’s Rule 23 findings on market efficiency, price impact, and whether a classwide damages methodology could measure alleged losses tied to claimed artificial inflation and later corrective disclosures.
The record reflects that Teva became involved in private securities litigation beginning in or around November 2016, when investors first filed actions alleging misleading statements about the company’s financial condition. These early cases later became part of a broader set of related investor claims that developed over time. The alleged harm theory centered on investor losses following market reactions to information tied to generic-drug pricing and competition, placing healthcare industry economics at the center of the dispute.
The first-filed lawsuit was transferred from the Central District of California to the U.S. District Court for the District of Connecticut in April 2017. After transfer, the matter proceeded under the procedural framework governing federal securities class actions, including lead-plaintiff and lead-counsel appointment processes. The allegations continued to focus on Teva’s investor-facing disclosures regarding performance in the generic-drug market.
In July 2017, the court appointed Ontario Teachers’ Pension Plan Board as lead plaintiff and approved Bleichmar Fonti & Auld LLP as lead counsel. That appointment established the leadership structure for pursuing the claims on behalf of the proposed class. The litigation continued to develop around whether statements and omissions concerning generic-drug pricing strategy and competitive conditions were materially misleading to investors.
On September 25, 2019, the court granted in part and denied in substantial part the defendants’ motion to dismiss the Second Amended Consolidated Class Action Complaint. This ruling allowed significant portions of the case to proceed beyond the pleadings stage while narrowing the claims that remained in dispute. The surviving issues continued to address whether the market was misled about the drivers of Teva’s financial results in a pricing-pressured healthcare drug environment.
By early 2020, the Teva securities actions were proceeding under consolidated case management in the District of Connecticut. The court entered a consolidation order dated March 10, 2020, aligning overlapping actions under a unified structure and coordinated case-management approach. This procedural step set the stage for class proceedings where marketwide proof and common evidence became central.
On June 19, 2020, the class representatives filed a motion for class certification. The record reflects extensive briefing and expert discovery, including the exchange of expert reports and multiple expert depositions, as the parties litigated classwide proof issues. The certification record included plaintiffs’ market-efficiency analysis offered by Dr. Tabak, along with defense expert reports from Dr. Mukesh Bajaj and Dr. John McConnell challenging the reliability and interpretation of that analysis. Defendants also relied on an expert report from Christopher M. James addressing Teva’s disclosures, publicly available and commercial drug-pricing data, analyst coverage, and issues related to isolating damages across multiple liability theories, all presented for Rule 23 purposes.
On March 9, 2021, the court granted the motion for class certification and appointed Ontario Teachers’ Pension Plan Board and Anchorage Police & Fire Retirement System as class representatives, with Bleichmar Fonti & Auld LLP as class counsel. In the same decision set, the court denied a Daubert motion directed at Dr. Tabak’s market-efficiency analysis, while also evaluating and rejecting defense critiques offered by Dr. Mukesh Bajaj and Dr. John McConnell, as well as damages-related arguments supported by Christopher M. James. The court concluded that the plaintiffs satisfied Rule 23 requirements based on common evidence, expressly noting that these expert disputes were resolved solely for class-certification purposes and did not constitute findings on liability or ultimate merits.
Settlement materials describe a stipulation dated January 18, 2022 setting out a proposed resolution of the litigation. The proposal contemplated a $420,000,000 cash settlement fund, subject to court approval and a formal notice process for class members. The settlement presentation framed investor losses as tied to market pricing responses to information concerning competition and pricing dynamics in the generic-drug segment.
The long-form settlement notice set May 2, 2022 as the deadline for class members to submit written requests for exclusion. The notice also described deadlines for objections and for filing notices of intention to appear. These procedural steps reflect standard resolution mechanics in securities class actions focused on market impact and investor-loss calculations.
The long-form notice scheduled a settlement hearing for June 2, 2022, at which the court considered whether to approve the proposed settlement. Case summaries and settlement materials describe the court granting final approval of the $420 million settlement on the hearing date. The approved settlement resolved claims tied to purchases or acquisitions of specified Teva securities during defined periods, with eligibility and allocation governed by the settlement terms.
The court addressed a Daubert challenge directed at Dr. Tabak and allowed his market-efficiency analysis to remain part of the class-certification record. The decision describes his training in economics and his experience in economic consulting as part of the court’s evaluation of his qualifications for the Rule 23 market-efficiency inquiry. His work addressed whether Teva securities traded in an efficient market using recognized factors and event-study style testing tied to price responsiveness.
The defendants presented Dr. Mukesh Bajaj and Dr. John McConnell to challenge the plaintiffs’ market-efficiency showing. Their critiques focused on the reliability, interpretation, and design of the plaintiffs’ event-study-based analyses. The court evaluated these critiques and concluded they did not defeat plaintiffs’ Rule 23 showing for certification purposes.
The record describes an expert report submitted by Christopher M. James addressing Teva’s public disclosures, publicly available drug-pricing data, analyst coverage, and issues related to isolating damages across multiple liability theories. The court rejected defendants’ arguments relying on this report for purposes of predominance and damages methodology at the class-certification stage.
In pharmaceutical securities litigation, economics experts are commonly engaged to explain competitive conditions, pricing behavior, and how market disclosures relate to investor expectations and securities pricing.
Forensic accounting experts are often consulted to analyze financial statements, earnings narratives, and disclosure practices in cases alleging misleading statements about business performance.
Market-efficiency proof determined whether reliance and price impact could be addressed with common evidence at class certification.
The court evaluated expert critiques without converting certification rulings into merits determinations.
Clear definitions reduced ambiguity in settlement administration and loss allocation.
Notice procedures, opt-out deadlines, and claims processing shaped resolution leverage and finality.
Although pricing and competition framed the dispute, the court’s analysis focused on disclosure materiality, market impact, and Rule 23 proof.
The Teva securities litigation in the District of Connecticut progressed from allegations about generic-drug pricing disclosures to coordinated class proceedings testing whether marketwide proof could support investor claims. The court’s class-certification rulings and expert-related decisions positioned the matter for resolution, culminating in a $420 million settlement approved through a court-supervised notice and approval process.
The case illustrates how economics, market efficiency, and structured damages methodologies intersect with securities procedure, particularly in healthcare-industry disputes involving pricing and competition narratives.
What was the core issue raised by investors?
Investors alleged that Teva’s disclosures misrepresented the drivers of its generic-drug business performance.
Why was market efficiency central to the case?
Market efficiency determined whether reliance and price impact could be addressed on a classwide basis.
What did the court decide at class certification?
The court found Rule 23 requirements satisfied and declined to exclude plaintiffs’ market-efficiency expert.
Which securities were covered by the settlement?
The settlement covered specified Teva ADS, preferred shares, and certain senior notes during defined periods.
How does the $420 million settlement relate to damages?
The settlement reflects negotiated risk and does not constitute a judicial damages finding.
Why is this case cited in healthcare securities litigation?
It demonstrates how drug-pricing narratives translate into securities-law questions about disclosure, market impact, and classwide proof.
The court addressed a Daubert challenge directed at Dr. Tabak and allowed his market-efficiency analysis to remain part of the class-certification record. The decision describes his training in economics and his experience in economic consulting as part of the court’s evaluation of his qualifications for the Rule 23 market-efficiency inquiry. His work addressed whether Teva securities traded in an efficient market using recognized factors and event-study style testing tied to price responsiveness.
The defendants presented Dr. Mukesh Bajaj and Dr. John McConnell to challenge the plaintiffs’ market-efficiency showing. Their critiques focused on the reliability, interpretation, and design of the plaintiffs’ event-study-based analyses. The court evaluated these critiques and concluded they did not defeat plaintiffs’ Rule 23 showing for certification purposes.
The record describes an expert report submitted by Christopher M. James addressing Teva’s public disclosures, publicly available drug-pricing data, analyst coverage, and issues related to isolating damages across multiple liability theories. The court rejected defendants’ arguments relying on this report for purposes of predominance and damages methodology at the class-certification stage.
In pharmaceutical securities litigation, economics experts are commonly engaged to explain competitive conditions, pricing behavior, and how market disclosures relate to investor expectations and securities pricing.
Forensic accounting experts are often consulted to analyze financial statements, earnings narratives, and disclosure practices in cases alleging misleading statements about business performance.
Market-efficiency proof determined whether reliance and price impact could be addressed with common evidence at class certification.
The court evaluated expert critiques without converting certification rulings into merits determinations.
Clear definitions reduced ambiguity in settlement administration and loss allocation.
Notice procedures, opt-out deadlines, and claims processing shaped resolution leverage and finality.
Although pricing and competition framed the dispute, the court’s analysis focused on disclosure materiality, market impact, and Rule 23 proof.
The Teva securities litigation in the District of Connecticut progressed from allegations about generic-drug pricing disclosures to coordinated class proceedings testing whether marketwide proof could support investor claims. The court’s class-certification rulings and expert-related decisions positioned the matter for resolution, culminating in a $420 million settlement approved through a court-supervised notice and approval process.
The case illustrates how economics, market efficiency, and structured damages methodologies intersect with securities procedure, particularly in healthcare-industry disputes involving pricing and competition narratives.
What was the core issue raised by investors?
Investors alleged that Teva’s disclosures misrepresented the drivers of its generic-drug business performance.
Why was market efficiency central to the case?
Market efficiency determined whether reliance and price impact could be addressed on a classwide basis.
What did the court decide at class certification?
The court found Rule 23 requirements satisfied and declined to exclude plaintiffs’ market-efficiency expert.
Which securities were covered by the settlement?
The settlement covered specified Teva ADS, preferred shares, and certain senior notes during defined periods.
How does the $420 million settlement relate to damages?
The settlement reflects negotiated risk and does not constitute a judicial damages finding.
Why is this case cited in healthcare securities litigation?
It demonstrates how drug-pricing narratives translate into securities-law questions about disclosure, market impact, and classwide proof.
Securities Class Action
Securities Fraud
Securities Litigation
Financial Analysis
Economic Analysis
Institutional investor
Investment Fraud
Pharmacoeconomics
Pharmaceutical, +4
Pharmaceutical
Pharmaceutical, +4
Pharmaceutical